# A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

> **NCT07569081** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 192 (estimated)

## Conditions studied

- VEXAS Syndrome

## Interventions

- **DRUG:** Momelotinib
- **DRUG:** Glucocorticoids
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07569081
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-05
- **Primary completion:** 2028-12-06
- **Final completion:** 2031-06-04
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07569081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07569081, "A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07569081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*